Golden logoGolden logo
Advanced Search
AbCellera Biologics

AbCellera Biologics

Vancouver-based company focused on antibody discovery for therapeutics and immune profiling for vaccine research.

AbCellera is a privately held company in Vancouver, Canada focused on antibody discovery for therapeutics and immune profiling for vaccine research. AbCellera partners with researchers in academia, non-profit organizations and industry to help accelerate the development of new antibody therapies and new vaccines.


The company has a single-cell platform that integrates proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation and laboratory automation. Single B cells are screened for natural immune responses and the production of antibodies from any species.

Celium is AbCellera’s proprietary antibody visualization software. Celium is a data mining and visualization tool that combines computation with genomics and high-throughput microfluidics and is able to test millions of antibody variants in a single day. Millions of individual immune cells each make a unique antibody molecule and the AbCellera team collects data about the initial target antigen, the immune response to that antigen and the binding properties, antibody sequences and their relatedness to others. Other biophysical characteristics related to the potential to manufacture the antibody as an effective drug, such as expression level and stability, are also analysed. Celium makes the large amount of data easier for humans to explore and find patterns. Celium provides a user interface where antibodies with similar DNA sequences or similar biological functions are linked in a visual space.

Abcellera works under the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program to develop a technology platform capable of developing field-ready medical countermeasures within 60 days after a viral pathogen is isolated. Abcellera is working on an antibody-based method to neutralize and block transmission of SARS-CoV-2 (2019-nCoV), the new coronavirus responsible for the outbreak declared a global emergency by the World Health Organization (WHO). The coronavirus strain has more recently been renamed SARS-CoV-2 with the disease called COVID-19 (coronavirus disease). The company’s approach is to deliver a nucleic acid vector that will be translated into the antibody protein within the patient. AbCellera and Eli Lilly entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19 on March 12, 2020.

Grant I

On September 27, 2013 AbCellera Biologics announced receiving a grant worth an undisclosed amount of money from an undisclosed source.


On August 9, 2014 AbCelllera Biologics announced raising an undisclosed round of seed funding from undisclosed investors.

Venture round

On April 4, 2017 AbCellera Biologics announced raising $817, 900 in funding from undisclosed investors.

Series A

On September 27, 2018 AbCellera Biologics announced raising $10 million in series A funding from Data Collective DCVC. The company plans on using their series A funding to accelerate the development of their therapeutic antibody discovery business and to improve its technological capabilities for computation, protein engineering, and immune repertoire profiling. At the time of announcing their series A funding AbCellera Biologics also announced Doug Janzen stepping down from his position as the company's Chairman of the Board.

Grant II

On March 14, 2019 AbCellera announced receiving a grant worth $4.8 million from the Bill & Melinda Gates Foundation.


June 1, 2020
AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment
May 27, 2020
AbCellera Biologics raises a $105,000,000 series B round from DCVC Bio, Eli Lilly and Company, Founders Fund, OrbiMed, Peter Thiel, Presight Capital and Viking Global Investors.
May 3, 2020
AbCellera Receives $175.6 million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs
May 3, 2020
AbCellera Biologics raises a $175,600,000 grant from Government of Canada.
May 14, 2019
AbCellera Biologics raises a $4,800,000 grant from Bill & Melinda Gates Foundation.
September 27, 2018
AbCellera raises Series A round

Vancouver, British Columbia-based AbCellera, a developer of next-generation therapeutic antibodies, has raised $10 million in Series A financing.

September 27, 2018
AbCellera Biologics raises a $10,000,000 series A round from Data Collective.
April 4, 2017
AbCellera Biologics raises a $817,900 venture round.
AbCellera Biologics was founded by Carl Hansen, Kevin Heyries and Véronique Lecault.

Funding Rounds


Further Resources




Case study on AbCellera




Isabelle Kirkwood
May 10, 2021
Montréal-based venture capital firm CTI Life Sciences Fund has raised $100 million CAD in the first close of its third venture fund. The fund's...
May 4, 2021
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials - read this article along with other careers information, tips and advice on BioSpace
April 14, 2021
AbCellera (Nasdaq: ABCL) and Empirico Inc. ("Empirico") announced today that they have entered into a strategic multi-target discovery collaboration.
Colin McClelland
November 24, 2020
Canada's biotech health-care industry is booming amid the pandemic but industry faces challenges
Colin McClelland
December 11, 2020
AbCellera stock price shoots up 185% in its debut on the Nasdaq stock exchange


Golden logo
By using this site, you agree to our Terms of Service.